Table 4 Surgeons initial SAP type decision, App recommended type (in accordance to WHO/ Sanford guidance) and surgeons final SAP type decision during the intervention project (N = 321)
SAP combination | Initial N (%) | App N (%) | Final N (%) |
|---|---|---|---|
No SAP | 5 (1.5) | 132 (41.1) | 35 (10.9)) |
AB combination covering gram-pos, gram-neg and anaerobs*1 | 154 (48) | 57 (17.8) | 139 (43.3) |
Fluoroquinolone | 112 (34.9) | 3 (0.9) | 102 (31.8) |
1st gen Cephalosporin | 1 (0.3) | 86 (26.8) | 4 (1.2) |
2nd & 3rd gen Cephalosporin | 24 (7.5) | 4 (1.2) | 19 (5.9) |
Clindamycin + Gentamicin or Ciprofloxacin or Aztreonam | 1 (0.3) | 4 (1.2) | 1 (0.3) |
Fluoroquinolone or Chloramphenicol ophthalmic solution | 14 (4.4) | 0 | 14 (4.4) |
Doxycycline | 0 | 5 (1.6) | 0 |
No recommendation recorded*2 | 14 (4.4) | ||
Other | 10 (3.1) | 16 (5) | 7 (2.2) |
Total | 321 | 321 | 321 |